$14.37
-0.55-3.69%
Last update: Oct 23, 4:00 PM
Cullinan Therapeutics Inc (CGEM) Stock Price, Quote, News & History
CGEMNASDAQ
Cullinan Therapeutics and Taiho report positive Phase 3 trial results for zipalertinib in treating advanced lung cancer.
You can purchase shares of Cullinan Therapeutics (NASDAQ:CGEM) through any online brokerage.
Other companies in Cullinan Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Cullinan Therapeutics has a consensus price target of $30.17.
The stock price for Cullinan Therapeutics (NASDAQ: CGEM) is $14.37 last updated October 23, 2026 at 4:00 PM EDT.
There are no upcoming dividends for Cullinan Therapeutics.
Cullinan Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Cullinan Therapeutics.
Cullinan Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is...
